Displaying drugs 2226 - 2250 of 2712 in total
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Iupac: … N-[(1R,3S,5S)-8-[2-(4-acetylpiperazin-1-yl)ethyl]-8-azabicyclo[3.2.1]octan-3-yl]-1-(propan-2-yl)-1H-indazole …
1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
Experimental
Molnupiravir
Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of N4-hydroxycytidine.[A193014,A193026] With improved oral bioavailability in non-human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5’-triphosphate form. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as...
Investigational
Redaporfin
Investigational
Quinonoid 7,8-Tetrahydrobiopterin
Experimental
Pegozafermin
Pegozafermin is under investigation in clinical trial NCT05852431 (To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia).
Investigational
1,8-Di-Hydroxy-4-Nitro-Anthraquinone
Experimental
Mixed Carbamic Phosphoric Acid Anhydride of 7,8-Diaminononanic Acid
Experimental
Matched Iupac: … (7R,8S)-8-amino-7-{[(phosphonooxy)carbonyl]amino}nonanoic acid …
Magrolimab
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Investigational
AZD-6280
AZD6280 has been used in trials studying the basic science of Anxiety.
Investigational
Matched Iupac: … 4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide …
Strychnine
Experimental
Matched Iupac: … (1R,11S,18S,20R,21R,22S)-12-oxa-8,17-diazaheptacyclo[15.5.2.0^{1,18}.0^{2,7}.0^{8,22}.0^{11,21}.0^{15,20 …
5beta-dihydrotestosterone
Experimental
Dihydromorphine
A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Experimental
Illicit
Matched Iupac: … (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10 …
5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
Experimental
Matched Iupac: … 7-[(2-aminoethyl)amino]-9-fluoro-5-(1H-pyrrol-2-yl)-2-azatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12 …
10-formyl-5,8,10-trideazafolic acid
Experimental
6,8-DIMERCAPTO-OCTANOIC ACID AMIDE
Experimental
Etoperidone
Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile. Etoperidone was developed by Angelini Francesco ACRAF.
Withdrawn
Azapropazone
Withdrawn
Matched Iupac: … (4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0^{2,6}]trideca-1(13), …
BC9KBY85WY
Investigational
INHIBITOR Q8467 OF DUPONT MERCK
Experimental
KIN-3248
KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. While effective, disease progression may occur 6 to 8 months...
Investigational
Matched Description: … [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently …
Displaying drugs 2226 - 2250 of 2712 in total